SEC Comment Letter 0000000000-24-001317 to Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: Feb. 2, 2024 · CIK: 0001611747 · Accession: 0000000000-24-001317
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276767
Letter
United States securities and exchange commission logo February 2, 2024 Amir Reichman Chief Executive Officer Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2nd Floor Kiryat Hadassah, Building 1, JBP Jerusalem, Israel 9112001 Re:Scinai Immunotherapeutics Ltd. Registration Statement on Form F-3 Filed January 30, 2024 File No. 333-276767 Dear Amir Reichman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven A. Lipstein
Show Raw Text
United States securities and exchange commission logo
February 2, 2024
Amir Reichman
Chief Executive Officer
Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2nd Floor
Kiryat Hadassah, Building 1, JBP
Jerusalem, Israel 9112001
Re:Scinai Immunotherapeutics Ltd.
Registration Statement on Form F-3
Filed January 30, 2024
File No. 333-276767
Dear Amir Reichman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven A. Lipstein